Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
10.61
+0.54 (5.36%)
At close: Jun 22, 2026, 4:00 PM EDT
10.81
+0.20 (1.89%)
After-hours: Jun 22, 2026, 6:26 PM EDT
Atara Biotherapeutics Employees
Atara Biotherapeutics had 13 employees as of March 31, 2026. The number of employees decreased by 76 or -85.39% compared to the same quarter last year.
Employees
13
Change
-76
Growth
-85.39%
Revenue / Employee
$1,779,923
Profits / Employee
-$728,231
Market Cap
95.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 13 | -76 | -85.39% |
| Dec 31, 2025 | 14 | -139 | -90.85% |
| Sep 30, 2025 | 38 | -121 | -76.10% |
| Jun 30, 2025 | 38 | -127 | -76.97% |
| Mar 31, 2025 | 89 | -84 | -48.55% |
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Sep 30, 2024 | 159 | -149 | -48.38% |
| Jun 30, 2024 | 165 | -152 | -47.95% |
| Mar 31, 2024 | 173 | -157 | -47.58% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Sep 30, 2023 | 308 | -32 | -9.41% |
| Jun 30, 2023 | 317 | -117 | -26.96% |
| Mar 31, 2023 | 330 | -240 | -42.11% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Sep 30, 2022 | 340 | -238 | -41.18% |
| Jun 30, 2022 | 434 | -124 | -22.22% |
| Mar 31, 2022 | 570 | 90 | 18.75% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Seer, Inc. | 124 |
| Inovio Pharmaceuticals | 112 |
| PolyPid | 75 |
| Cue Biopharma | 29 |
| NeurAxis | 24 |
| Black Diamond Therapeutics | 21 |
| ProMIS Neurosciences | 11 |
ATRA News
- 10 days ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 11 days ago - Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia - GlobeNewsWire
- 13 days ago - Atara Biotherapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Atara Biotherapeutics upgraded to Hold from Sell at Freedom Broker - TheFly
- 5 weeks ago - Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c - TheFly
- 5 weeks ago - Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - Business Wire
- 5 weeks ago - Atara Biotherapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Atara Biotherapeutics Earnings release: Q1 2026 - Filings